CR11745A - USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATIN LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONA - Google Patents

USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATIN LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONA

Info

Publication number
CR11745A
CR11745A CR11745A CR11745A CR11745A CR 11745 A CR11745 A CR 11745A CR 11745 A CR11745 A CR 11745A CR 11745 A CR11745 A CR 11745A CR 11745 A CR11745 A CR 11745A
Authority
CR
Costa Rica
Prior art keywords
dronedarona
increase
patients
treatment
administration
Prior art date
Application number
CR11745A
Other languages
Spanish (es)
Inventor
Claudel Sophie
Gaudin Christophe
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CR11745A publication Critical patent/CR11745A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilización de dronedarona o una de sus sales aceptables farmacéuticamente para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo dichos pacientes un incremento en el nivel de creatinina debido a la administración de dronedarona, incrementándose dicho nivel de creatinina después del inicio del tratamiento con dronedarona, alcanzando dicho incremento del nivel de creatinina un plató y utilizándose como una línea base nueva, siendo dicho incremento dle nivel de creatinina reversible después de la suspensión de la dronedarona.Use of dronedarone or one of its pharmaceutically acceptable salts to prepare a medicament for the treatment of patients with arrhythmia, said patients having an increase in creatinine level due to the administration of dronedarone, said creatinine level increasing after the start of treatment with dronedarone, said increase in creatinine level reaching a set and being used as a new baseline, said increase in reversible creatinine level after dronedarone suspension.

CR11745A 2008-04-28 2010-10-21 USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATIN LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONA CR11745A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4873208P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
CR11745A true CR11745A (en) 2011-02-18

Family

ID=51359610

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11745A CR11745A (en) 2008-04-28 2010-10-21 USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATIN LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONA

Country Status (1)

Country Link
CR (1) CR11745A (en)

Similar Documents

Publication Publication Date Title
CL2016002132A1 (en) Use of an amount of laquinimod, which is used to prepare a medication to treat a human patient affected with multiple sclerosis or who has a clinically isolated syndrome; a package, an amount of laquinimod and a pharmaceutical composition thereof.
AR089862A1 (en) USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH CROHN'S DISEASE IN THOSE WHO FAILS AN ANTI-FACTOR THUMOR NECROSIS THERAPY a (ANTI-TNFa) FIRST LINE
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
CL2011000798A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
PE20150161A1 (en) USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS
NI201000181A (en) USE OF DRONEDARONE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRHYTHMIA AND WHO HAVE AN INCREASED CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONE.
CL2011000806A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
CO7151496A2 (en) Therapeutic agents for optimized subcutaneous administration
PE20181332A1 (en) METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE
AR072951A1 (en) USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REGULATE THE LEVEL OF POTASSIUM IN THE BLOOD
CO6361995A2 (en) ISOQUINOLINONE DERIVATIVES AS AN NG3 ANTAGONISTS
CO6311083A2 (en) 4 - ((1R, 3S) -6-CHLORO-3-FENILINDAN-1-IL) -1,2,2-TRIMETHYLIPIPERAZINE FOR THE TREATMENT OF COGNITIVE DYSFUNCTION
ECSP16086232A (en) (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
ES2616035T3 (en) Preparation for use in the prophylaxis and treatment of atypical osteoporosis
AR082501A1 (en) THERAPEUTIC USES OF 1- [2- (2,4-DIMETHYL-PHENYLSULPHANIL) PHENYL] PIPERAZINE
ECSP10010464A (en) USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
AR075866A1 (en) A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION
DOP2012000012A (en) OTAMIXABAN FOR THE TREATMENT OF PATIENTS WITH RENAL ALTERATION AND ADVANCED AGE WITH INFARTO OF MIOCARDIO WITHOUT ELEVATION OF THE ST
ECSP15033649A (en) A COMBINED MEDICINAL PRODUCT INCLUDING PHENYLEPHRINE AND PARACETAMOL
CR11745A (en) USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATIN LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONA
UY32985A (en) USE OF CELIVARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATININE LEVEL DUE TO THE ADMINISTRATION OF CELIVARONA
AR061046A1 (en) MIRTAZAPINE FOR THE TREATMENT OF NEUROPATHIC PAIN
UY31669A1 (en) "PHARMACEUTICAL FORMULATION THAT INCLUDES OXABISPIDINS / 236"

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)